In yesterday’s Wall Street session, Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) shares traded at $22.42, up 0.95% from the previous session.
TEVA stock price is now 24.53% away from the 50-day moving average and 34.10% away from the 200-day moving average. The market capitalization of the company currently stands at $25.45B.
With the price target maintained at $20, Argus recently Upgraded its rating from Hold to Buy for Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA). On March 08, 2024, JP Morgan Upgraded its previous ‘Underweight’ rating to ‘Neutral’ on the stock keeping its target price maintained at $14, while ‘Piper Sandler’ rates the stock as ‘Overweight’
In other news, Bridger Management, LLC (1), Shareholder bought 286,000 shares of the company’s stock on Dec 20 ’24. The stock was bought for $6,094,660 at an average price of $21.31. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 20 ’24, EVP, Head of U.S. Commercial Fox Christine sold 19,388 shares of the business’s stock. A total of $327,085 was realized by selling the stock at an average price of $16.87. This leaves the insider owning 44,104 shares of the company worth $0.99 million. A total of 0.01% of the company’s stock is owned by insiders.
During the past 12 months, Teva- Pharmaceutical Industries Ltd. ADR has had a low of $10.34 and a high of $22.25. As of last week, the company has a debt-to-equity ratio of 3.18, a current ratio of 0.89, and a quick ratio of 0.61. The fifty day moving average price for TEVA is $17.8994 and a two-hundred day moving average price translates $16.6729 for the stock.
The latest earnings results from Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) was released for 2024-09-30. The net profit margin was -5.72% and return on equity was -14.76% for TEVA. The company reported revenue of $4.33 billion for the quarter, compared to $3.85 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 12.52 percent.
